Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

59.27 +0.53 (+0.90%)
Official Closing Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
66 67 Next >
2 Absurdly Cheap Healthcare Stocks to Buy and Hold for Decades
You won't have to worry about paying a premium for either one of these stocks -- and they both pay a solid dividend. 
Via The Motley Fool
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
From Bristol Myers Squibb
Via Business Wire
Meta, Amazon And 3 Stocks To Watch Heading Into Thursday
With U.S. stock futures trading lower this morning on Thursday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Fear Continues To Grip Markets As S&P 500 Settles Below 4,200
The CNN Money Fear and Greed index showed growth easing in the overall fear level, remaining in the "Fear" zone on Wednesday. U.S. stocks closed lower on Wednesday, with the S&P 500 closing the session... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why LianBio Stock Is Skyrocketing Today
Investors are loving LianBio's new deal with Bristol Myers Squibb. 
Via The Motley Fool
What 12 Analyst Ratings Have To Say About Bristol-Myers Squibb
Via Benzinga
3 Things About Bristol Myers Squibb That Smart Investors Know
The stock is down this year, but will its struggles fade into the rearview mirror? 
Via The Motley Fool
META Up +4% On +23% Revenue Growth; IBM And NOW Also Beat
Markets sagged throughout the course of today’s trading session after starting mixed, with the Dow basking in Microsoft’s stellar previous-afternoon’s earnings report. 
Via Talk Markets
Topics Stocks
Exposures US Equities
This Artificial Intelligence (AI) Stock Is Powering the Biotech Revolution: Should You Invest?
There's more to the AI boom than Microsoft and ChatGPT. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Is LianBio (LIAN) Stock Up 130% Today?
With LianBio inking a key exclusive licensing agreement with Bristol-Myers Squibb, LIAN stock is jumping up on the credibility implications. 
Via InvestorPlace
Why LianBio Stock Is Ripping Higher Today
LianBio (NASDAQ: LIAN) shares are trading higher Tuesday after the company announced an agreement with Bristol Myers Squibb (NYSE: BMY) to purchase LianBio's exclusive rights to develop and... 
Via Benzinga
'Never Buy A Drug Stock Just For The Yield': Jim Cramer On This Big Pharma Company
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended selling Petróleo Brasileiro S.A. - Petrobras (NYSE: PBR). 
Via Benzinga
2 High-Yield Dividend Stocks to Buy Now
These two blue-chip stocks sport generous yields. 
Via The Motley Fool
Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
From Bristol Myers Squibb
Via Business Wire
Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market?
Factset data indicates that out of the 17% of the S&P 500 companies that have reported so far, 73% have reported positive EPS surprises. 
Via Benzinga
Topics Stocks
Exposures US Equities
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
The venerable pharmaceutical companies' shares have slumped this year. 
Via The Motley Fool
Investor Risk Sentiment Wavers Amid War, Interest Rate Concerns; Tesla Earnings Disappoint: The Week In The Markets
In the week ahead, earnings season moves into full swing with reports from companies like Microsoft, Alphabet, Meta Platforms and Amazon. 
Via Benzinga
7 Healthcare Stocks That Can Cure a Lackluster Portfolio
Take a position in these companies' stocks to achieve long-term gains and give a jolt to your investment portfolio. 
Via InvestorPlace
Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings
Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced or... 
Via Benzinga
Could Bristol Myers Squibb Stock Help You Become a Millionaire?
Bristol Myers has been investing in growth, but will it be enough to get investors bullish on its struggling stock? 
Via The Motley Fool
Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
The Robert A. Winn Diversity in Clinical Trials Award Announces Third Group of Physicians in Program to Increase Diversity in Clinical Trials
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Highlights Opdivo Regime Data In Lung Cancer Settings
Bristol Myers Squibb & Co (NYSE: BMY) announced the first disclosure of data from the Phase 3 CheckMate -77T trial of the perioperative regimen of neoadjuvant Opdivo (nivolumab) with chemotherapy... 
Via Benzinga
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Provides Benefits for Patients with Resectable Non-Small Cell Lung Cancer Across PD-L1 Expression Levels with Three-Year Follow Up in CheckMate -816 Trial
From Bristol Myers Squibb
Via Business Wire
Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Followed by Opdivo Demonstrates Significant Survival Benefits for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in Phase 3 CheckMate -901 Trial
From Bristol Myers Squibb
Via Business Wire
Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial
From Bristol Myers Squibb
Via Business Wire
2 Biotech Stocks That Could Make You Richer
These two well-known drugmakers still have some growth fuel in their seemingly empty tanks. 
Via The Motley Fool
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
Major pharmaceutical companies are continuing to make substantial acquisitions in the field of oncology, sparking enthusiasm in the market. Bristol Myers Squibb (NYSE:BMY) just announced its plan to... 
Via PressReach
FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda for resectable (tumors ≥4 centimeters [cm] or node-positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing... 
Via Benzinga
Exposures Product Safety
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq – CNSL), Mirati Therapeutics, Inc.® (Nasdaq - MRTX), Pioneer Natural Resources (NYSE - PXD), Summit Materials (NYSE
From Brodsky & Smith LLC
Via GlobeNewswire
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
66 67 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.